Skip to main content

Rheumatoid Arthritis

      Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in rheumatology, and the consequent frequency of patient counselling about it, relatively little is known about what precautions are absolutely required, a situation which might otherwise provoke anxiety for patients.
      RT @DrMiniDey: Plenary Abs#1427 #ACR21
      👉🏼#Statins assoc w/ reduced #CVD & all-cause mortality, outweighing
      mod

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Plenary Abs#1427 #ACR21 👉🏼#Statins assoc w/ reduced #CVD & all-cause mortality, outweighing modest #T2DM risk increase in RA pts 👉🏼Reduction in all-cause mortality greater in RA than gen population 👉🏼Incr in T2DM risk is NOT greater in RA compared to gen population @RheumNow https://t.co/WcF11B0C2s
      RT @bella_mehta: Statins in RA - plenary at #ACR21 UK Clinical
      Practice Research Datalink 1989-2018 @RheumNow
      Reduction

      Bella Mehta bella_mehta

      3 years 11 months ago
      Statins in RA - plenary at #ACR21 UK Clinical Practice Research Datalink 1989-2018 @RheumNow Reduction in CVD risk, All cause mortality INCREASE in Type 2 DM risk🧐 - need to make sure we look into it for RA patients! Great work @UNMC_Rheum by Gulsen Ozen! https://t.co/YmTO0xcdjj
      RT @AurelieRheumo: RA and CVD: take your statins!
      Obs UK study
      Statins ⬇️CVD HR=0.46
      ⬇️All cause death HR=0.68

      Aurelie Najm AurelieRheumo

      3 years 11 months ago
      RA and CVD: take your statins! Obs UK study Statins ⬇️CVD HR=0.46 ⬇️All cause death HR=0.68 w/ mild ⬆️ T2DM risk HR=1.33 (but not more than in general population) ⭐️NNT to prevent CVD 102 ⭐️NNT to prevent death 46 ⭐️NNH 127 #ACR21 #Abst1427 @RheumNow https://t.co/v6TinuklNv https://t.co/r0rD4jMmuh
      RT @drdavidliew: In a telemedicine world where you can't palpate joints virtually, how can we use pt self-joint counts w

      David Liew drdavidliew

      3 years 11 months ago
      In a telemedicine world where you can't palpate joints virtually, how can we use pt self-joint counts well? Patients & rheums might not always rate the same, but: when RA pts say their joints are up or down, rheum exam usually agrees👍 @earlyarthritis #ACR21 ABST1203 @RheumNow https://t.co/spUNTlMnDY
      RT @ericdeinmd: #ACR21 Abst#1205- Discordance bw pt and MD global assessment in RA?
      ⭐️15% discordance (>30 mm dif

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abst#1205- Discordance bw pt and MD global assessment in RA? ⭐️15% discordance (>30 mm difference in GA score) ⭐️⬆️ in LDA and mod disease, ⬇️ remission/high disease ⭐️♂️ sex, pain VAS, normal CRP, less TJC&SJC predictive @Rheumnow https://t.co/N2qAaDiBE5
      RT @ericdeinmd: #ACR21 Abs#1210: Frequency of anterior atlanto-axial sublux in RA
      ⭐️Anterior atlanto-axial subluxati

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abs#1210: Frequency of anterior atlanto-axial sublux in RA ⭐️Anterior atlanto-axial subluxation (aAAS) = 3+ mm, frequency = 25% ⭐️Radicular pain 20%, surgery 6% ▶️Longer disease duration, ⬆️ frequency of extra-articular manifestations https://t.co/BfjCTlRJbt @Rheumnow https://t.co/xd9h5e9cDH
      RT @AurelieRheumo: #clinicalpearls Cervical involvement in RA: is it underestimated? Cohort of 240pts: anterior atlantoa

      Aurelie Najm AurelieRheumo

      3 years 11 months ago
      #clinicalpearls Cervical involvement in RA: is it underestimated? Cohort of 240pts: anterior atlantoaxial subluxation (aAAS) found in n=25 10.4 % patients, 1/3 with no neck pain! Joint restriction OR: 5.8 hx arthroplasty OR:3.6 #Abst1211 #ACR21 @RheumNow https://t.co/KRkDP4ETMu https://t.co/soKTMPiMwy
      RT @DrMiniDey: #RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      #RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than pts receiving biologic /other tsDMARD. 👉🏼Results from RA-BE-REAL observational study 👉🏼Bari(2 or 4mg) vs biologic/other tsDMARD Abs#1223 #ACR21 @RheumNow https://t.co/WRN1OCX9Bq https://t.co/UCFF6hAY7G
      RT @ericdeinmd: #ACR21 Abs#1224. ⬇️ CD39 expression on B cell predicts occurrence of anti-drug Ab in RA on RTX
      ⭐ï¸

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abs#1224. ⬇️ CD39 expression on B cell predicts occurrence of anti-drug Ab in RA on RTX ⭐️13/23 pts on RTX became ADAb+. No diff in concomitant MTX usage ⭐️Baseline CD73 similar, but lower CD39 predictive of ADAb https://t.co/QzbAmXtTmZ @Rheumnow https://t.co/CLtEev69YD
      RT @ericdeinmd: #ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA
      ⭐ï¸

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow
      RT @DrMiniDey: Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-na

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu
      ×